Reestablishment of p53/Arf and interferon-beta pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death

Autor(es):Mostrar menos -

Hunger, Aline ^[1] ; Medrano, V, Ruan F. ; Zanatta, Daniela B. ^[2] ; Del Valle, Paulo R. ^[2] ; Merkel, Christian A. ^[3] ; Salles, Thiago de Almeida ^[4] ; Ferrari, Daniel G. ^[5] ; Furuya, Tatiane K. ^[6] ; Bustos, Silvina O. ^[6] ; Saito, Renata de Freitas ^[6] ; Costanzi-Strauss, Eugenia ^[7] ; Strauss, Bryan E. ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Canc Inst Sao Paulo LIM 24, Viral Vector Lab, Ctr Translat Invest Oncol, Sch Med, Sao Paulo - Brazil

^[2] Medrano, Ruan F., V, Univ Sao Paulo, Canc Inst Sao Paulo LIM 24, Viral Vector Lab, Ctr Translat Invest Oncol, Sch Med, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Ctr Bioterismo, Sch Med, Anim Care Ctr, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Heart Inst InCor, Med Sch, Sao Paulo - Brazil

^[5] Univ Prebiteriana Mackenzie, Nat Comp Lab LCoN, Sao Paulo - Brazil

^[6] Univ Sao Paulo, Expt Oncol Lab, Ctr Translat Invest Oncol, Sch Med, Canc Inst Sao Paulo LIM 24, Sao Paulo - Brazil

^[7] Univ Sao Paulo, Biomed Sci Inst, Gene Therapy Lab, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: CELL DEATH DISCOVERY; v. 3, 2017.
• Citações Web of Science: 7

Resumo

Late stage melanoma continues to be quite difficult to treat and new therapeutic approaches are needed. Since these tumors often retain wild-type p53 and have a strong immunogenic potential, we developed a gene transfer approach which targets these characteristics. Previously, we have shown that combined gene transfer of p19Arf and interferon-beta (IFN beta) results in higher levels of cell death and superior immune-mediated antitumor protection. However, these experiments were performed using B16 cells (p53wt) with forced expression of the adenovirus receptor and also the mechanism of death was largely unexplored. Here we take advantage of a novel adenoviral vector (AdRGD-PG), presenting an RGD-modified fiber as well as a p53-responsive promoter, in order to investigate further potential benefits and cell death mechanisms involved with the combined transfer of the p19Arf and IFN beta genes to the parental B16 cell line. Simultaneous p19Arf and IFN beta gene transfer is more effective for the induction of cell death than single gene treatment and we revealed that p19Arf can sensitize cells to the bystander effect mediated by secreted IFN beta. Strikingly, the levels of cell death induced upon activating the p53/p19Arf and interferon pathways were higher in the presence of the AdRGD-PG vectors as compared to approaches using pharmacological mimetics and this was accompanied by the upregulation of antiviral response genes. Only combined gene transfer conferred immunogenic cell death revealed by the detection of key markers both in vitro and in vivo. Finally, whole-genome transcriptome analysis revealed unique expression profiles depending on gene function, including immune activation, response to virus and p53 signaling. In this way, cooperation of p19Arf and IFN beta activates the p53 pathway in the presence of an antiviral response elicited by IFN beta , culminating in immunogenic cell death. (AU)

• Processo FAPESP: 11/50911-4 - Elucidacao dos mecanismos moleculares que mediam a resposta da celulas de melanoma para a atividade combinada das vias de p53/arf e ifnb.
• Beneficiário: Bryan Eric Strauss
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 11/10656-5 - Avaliação dos mecanismos moleculares das vias de p53/ARF e IFN-beta envolvidos com a resposta de células de melanoma ao tratamento com os transgenes p19Arf e IFN-beta.
• Beneficiário: Aline Hunger Ribeiro
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 08/55963-0 - Transferência gênica de p19Arf e inferferon-beta em células de melanoma
• Beneficiário: Aline Hunger Ribeiro
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 13/09474-5 - Associação da imunoterapia mediada pela transferência gênica de p19Arf e interferon-beta com morte imunogênica induzida pelo quimioterápico doxorrubicina para o tratamento do câncer
• Beneficiário: Ruan Felipe Vieira Medrano
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 13/25167-5 - Transferência gênica de p19Arf e interferon-beta: delineando a importância de sua combinação em modelos murinos de terapia gênica do câncer
• Beneficiário: Bryan Eric Strauss
• Modalidade de apoio: Auxílio à Pesquisa - Regular